Kelyniam Global Inc. turns profitable during the second quarter of 2013
September 25 2013 - 8:37AM
Kelyniam Global Inc. (OTC: KLYG) ("the company") is pleased to
announce that it has posted its first ever quarterly profit, for
the quarter ending June 30, 2013. Net income for the second quarter
was $6,608. Sales in the second quarter were $593,355, up 35% from
$438,415 in the first quarter 2013. Year to date sales were
$1,031,770, up 253% from the same period in 2012. The company
continues to deploy capital towards marketing and organic growth,
and to build market share as its customized PEEK implants are sold
in more hospitals than ever. It has recently negotiated better
terms for the DECD note secured last year, with the term of the
note changing from 5 years to 10 without any increase in the
interest rate. Kelyniam will be an active participant in the
Connecticut Economic Trade Mission to Australia later this week,
traveling to both Sydney and Canberra, Australia. President &
CEO Tennyson Anthony exclaimed, "While we are pleased with our
second quarter performance, it is our goal to be used in all 50
states and internationally as well." He continued, "In fact,
our growth is not only focused on geography, but on building on our
existing products. The company will be announcing a new product in
the months to come, one that we feel will turn heads."
The company will be posting the financial tables on the website
www.kelyniam.com
About Kelyniam Global, Incorporated
Kelyniam Global (Pinksheets: KLYG), Inc. specializes in the use
of CAD/CAM technology to provide patient specific custom implants
to assist medical professionals by allowing them to operate more
effectively, improve patient care, and reduce health care costs by
providing the highest quality products available with today's
technology. The company is continually researching and developing
new products and processes to help patients live more active and
productive lives.
Please visit our website at www.kelyniam.com for more
information.
Forward-Looking Statements
Except for historical information contained in this release, the
matters discussed are forward-looking statements that involve risks
and uncertainties. When used in this release, words such as
"anticipate," "believes," "estimate," "expect," "should," "intend,"
"projects," "objective" and "appears" and similar expressions, as
they relate to the Company or its management, identify
forward-looking statements. Such forward-looking statements are
based on the beliefs of the Company's management, as well as
assumptions made by and information currently available to the
Company's management. Among the factors that could cause actual
results to differ materially are the following: the effect of
business and economic conditions; the impact of competitive
products and pricing; capacity and supply constraints or
difficulties; product development, commercialization or
technological difficulties; the regulatory and trade environment;
the impact of reimbursement rates and coverage; and the risk
factors reported from time to time in the Company's SEC reports.
The Company undertakes no obligation to revise any forward-looking
statements as a result of future events or developments.
Kelyniam Global (PK) (USOTC:KLYG)
Historical Stock Chart
From Nov 2024 to Dec 2024
Kelyniam Global (PK) (USOTC:KLYG)
Historical Stock Chart
From Dec 2023 to Dec 2024